{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:59:39Z","timestamp":1719003579368},"reference-count":46,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,3,15]]},"DOI":"10.2169\/internalmedicine.1216-22","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T22:11:11Z","timestamp":1690323071000},"page":"781-790","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study"],"prefix":"10.2169","volume":"63","author":[{"given":"Tomoyuki","family":"Saga","sequence":"first","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiyo","family":"Kanagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Yamawaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimichi","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kin-ikyo Chuo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fenaux P, Mufti GJ, Hellstrome-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Miyazaki Y. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-6 myelodysplastic syndromes (MDS). Int J Hematol 111: 481-493, 2020.","DOI":"10.1007\/s12185-020-02838-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199, 1982.","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 127: 2391-2405, 2016.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Helbig G, Chromik K, Wo\u017aniczka K, et al. Real life data on efficacy and safety of azacitidine therapy for myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia. Pathol Oncol Res 25: 1175-1180, 2019.","DOI":"10.1007\/s12253-018-00574-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Treppendahl MB, Kristensen LS, Gr\u00f8nb\u00e6k K. Predicting response to epigenetic therapy. J Clin Invest 124: 47-55, 2014.","DOI":"10.1172\/JCI69737"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Ogawa S. Genetics of MDS. Blood 133: 1049-1059, 2019.","DOI":"10.1182\/blood-2018-10-844621"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ginder GD. Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res 165: 115-125, 2015.","DOI":"10.1016\/j.trsl.2014.05.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Biss\u00e9 E, Wieland H. High-performance liquid chromatographic separation of human haemoglobins. Simultaneous quantitation of foetal and glycated haemoglobins. J Chromatogr 434: 95-110, 1988.","DOI":"10.1016\/0378-4347(88)80065-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wood WG. Increased HbF in adult life. In: Bailli\u00e8re&apos;s Clinical Haematology: International Practice and Research. Vol 1. Higgs DR, Weatherall DJ, Eds. Bailli\u00e8re Tindall, W. B. Saunders, London, 1993: 182.","DOI":"10.1016\/S0950-3536(05)80070-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Reinhardt D, Haase D, Schoch C, et al. Hemoglobin F in myelodysplastic syndrome. Ann Hematol 76: 135-138, 1998.","DOI":"10.1007\/s002770050377"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. L\u00fcbbert M, Ihorst G, Sander PN, et al. Elevated fetal haemoglobin is a predictor of better outcome in MDS\/AML patients receiving 5-aza-2&apos;-deoxycytidine (decitabine). Br J Haematol 176: 609-617, 2017.","DOI":"10.1111\/bjh.14463"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803, 2006.","DOI":"10.1002\/cncr.21792"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028, 2009.","DOI":"10.1038\/leu.2008.397"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49: 690-695, 2008.","DOI":"10.1080\/10428190701882146"},{"key":"16","first-page":"337","volume":"76","author":"KL Bourantas","year":"1991","unstructured":"16. Bourantas KL, Georgiou I, Seferiadis K. Quantitation of HbF \u03b3-chain types by HPLC in patients with myelodysplastic syndrome. Haematologica 76: 337-338, 1991.","journal-title":"Haematologica","ISSN":"http:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30: 649-657, 2016.","DOI":"10.1038\/leu.2015.283"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Stomper J, Ihorst G, Suciu S, et al. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica 104: 59-69, 2019.","DOI":"10.3324\/haematol.2017.187278"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Cheson BD, Greenberg PL, Benett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425, 2006.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanda Y. Investigation of the freely available easy-to-use software &apos;EZR&apos; for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088, 1997.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465, 2012.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Press KR, Uy N, Keefer J, et al. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. Leuk Lymphoma 59: 755-757, 2018.","DOI":"10.1080\/10428194.2017.1354373"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 98: 1067-1072, 2013.","DOI":"10.3324\/haematol.2012.074831"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Komrokji RS, Al Ali NH, Sallman D, et al. Validation of international Working Group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Cancer Medicine 10: 447-453, 2021.","DOI":"10.1002\/cam4.3608"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440, 2002.","DOI":"10.1200\/JCO.2002.04.117"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24: 3895-3903, 2006.","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Miyazaki Y, Kiguchi T, Sato S, et al. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. Int J Hematol 116: 228-238, 2022.","DOI":"10.1007\/s12185-022-03347-3"},{"key":"29","unstructured":"29. Kiguchi T. Optimization of azacitidine therapy for myelodysplastic syndrome. Ketsuekinaika (Hematology) 82: 881-887, 2021 (in Japanese)."},{"key":"30","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"30. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671-3674, 2000.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nazha A, Sekeres MA, Bejar R, et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. JCO Precis Oncol 3: PO.19.00119, 2019.","DOI":"10.1200\/PO.19.00119"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496-2506, 2011.","DOI":"10.1056\/NEJMoa1013343"},{"key":"33","unstructured":"33. Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. N Engl J Med Evidence 1: EVIDoa2200008, 2022."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Du M, Zhou F, Jin R, Hu Y, Mei H. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis. Leuk Res 80: 11-18, 2019.","DOI":"10.1016\/j.leukres.2019.03.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Papayannopoulou T. Control of fetal globin expression in man: new opportunities to challenge past discoveries. Exp Hematol 92: 43-50, 2020.","DOI":"10.1016\/j.exphem.2020.09.195"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bard H. The postnatal decline of hemoglobin F synthesis in normal full-term infants. J Clin Invest 55: 395-398, 1975.","DOI":"10.1172\/JCI107943"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science 188: 361-363, 1975.","DOI":"10.1126\/science.804182"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Huisman THJ, Harris H, Gravely ME. The chemical heterogeneity of the fetal hemoglobin in normal newborn and in adults. Mol Cell Biochem 17: 45-55, 1977.","DOI":"10.1007\/BF01732554"},{"key":"39","unstructured":"39. Matsuda A, Kusumoto S, Ito K, et al. Refractory anemia with excess of blasts (RAEB) with a high level of HbF that preceded apparent pancytopenia. Rinsho Ketsueki (Jpn J Clin Hematol) 37: 60-64, 1996 (in Japanese, Abstract in English)."},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. van der Ploeg LH, Flavell RA. DNA methylation in the human \u03b3\u03b4\u03b2-globin locus in erythroid and nonerythroid tissues. Cell 19: 947-958, 1980.","DOI":"10.1016\/0092-8674(80)90086-0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Mabaera R, Richardson CA, Johnson K, Hsu M, Fiering S, Lowrey CH. Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. Blood 110: 1343-1352, 2007.","DOI":"10.1182\/blood-2007-01-068635"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Vinjamur DS, Bauer DE, Orkin SH. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol 180: 630-643, 2018.","DOI":"10.1111\/bjh.15038"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Gong Y, Zhang X, Zhang Q, et al. A natural <i>DNMT1<\/i> mutation elevates the fetal hemoglobin level via epigenetic derepression of the \u03b3-glbin gene in \u03b2-thalassemia. Blood 137: 1652-1657, 2021.","DOI":"10.1182\/blood.2020006425"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Fluhr S, Krombholz CF, Meier A, et al. Epigenetic dysregulation of the erythropoietic transcription factor <i>KLF1<\/i> and the \u03b2-like globin locus in juvenile myelomonocytic leukemia. Epigenetics 12: 715-723, 2017.","DOI":"10.1080\/15592294.2017.1356959"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35: 1873-1889, 2021.","DOI":"10.1038\/s41375-021-01218-0"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 49: 204-212, 2017.","DOI":"10.1038\/ng.3742"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/6\/63_1216-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T03:31:27Z","timestamp":1710559887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/6\/63_1216-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1216-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"1216-22"}}